Document is current
Any future updates will be listed below
-
Authors
Wang, Fei
Banerjee, Victor https://orcid.org/0000-0002-3906-3362
Barria, Carla
Ramirez, Santiago
Allison, Tyler https://orcid.org/0009-0003-9513-8554
Gorski, Damian
Evans, Haley
Nguyen, Quynh
Harrison, Danielle https://orcid.org/0009-0000-8056-3038
Al-Lahham, Rabab
De Gregorio Carbonell, Nicole https://orcid.org/0000-0002-4433-9407
Pinho, Michelle
Kaalund, Sanne
Folke, Jonas https://orcid.org/0000-0002-0940-3098
Aznar, Susana
Concha-Marambio, Luis https://orcid.org/0000-0002-9454-8389
Ishtikhar, Mohd
Mallampalli, Venkata KPS
Pritzkow, Sandra
Shahnawaz, Mohammad
Baker, Matthew L. https://orcid.org/0000-0001-9039-8523
Serysheva, Irina
Soto, Claudio https://orcid.org/0000-0002-3412-0524
-
Funding
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson's Research (MJFF-019040)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS119689, R01NS119689)
- License Information
-
More Information
Article History
Received: 14 December 2023
Accepted: 31 October 2025
First Online: 10 December 2025
Competing interests
: Claudio Soto is a Founder, Chief Scientific Officer, consultant and shareholder of Amprion Inc., a biotechnology company that focuses on the commercial use of seed amplification assays for high-sensitivity detection of misfolded protein aggregates involved in various neurodegenerative diseases. Luis Concha is an employee of Amprion Inc. and Sandra Pritzkow also has a conflict in relation to Amprion. The University of Texas Health Science Center at Houston has licensed patents and patent applications to Amprion. The remaining authors declare no competing interests.
